DBV Technologies S.A.
DBVTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The $627.2M market capitalization puts DBVT squarely in small-cap range for its industry. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Market Cap
$627.2M
Beta
-0.24
P/E (TTM)
—
P/E (Fwd)
-20.47
EPS (TTM)
$-3.50
EPS (Fwd)
$-0.49
ROE
-142.7%
ROA
-60.6%
Cash
$174.9M
Total Debt
$7.7M
Free CF
-$104.8M
52W Change
-37.6%
Annual Financials
Cash vs Debt
Where DBVT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DBVT finished 44.01% below its 150-day moving average ($16.02) and 48.12% below its 200-day moving average ($17.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DBVT overbought or oversold?
At the October 20, 2026 close, DBVT's RSI(14) was 17.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $174.9M in cash and $7.7M in debt, DBVT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$104.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -142.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.24 suggests DBVT is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, DBVT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DBVT.